PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
May 30, 2026Journal of Clinical Oncology

Oncogenic EGFR amplification in EGFR-mutated NSCLC: EGFR subtype–dependent association with benefit from first-line osimertinib.

View Full Paper
Ask AI
Bookmark
Share

Authors

SMSaori MurataTYTatsuya YoshidaTOTakashi Ooe

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals EGFR amplification's impact on osimertinib efficacy varies by subtype in NSCLC, suggesting improved treatment strategies.

Key Points

  • To assess the association between EGFR amplification and the efficacy of first-line osimertinib in EGFR-mutated NSCLC, focusing on subtype differences.
  • Retrospective identification of advanced EGFR-mutated NSCLC patients receiving first-line osimertinib.
  • Analysis of genomic data from The Oncomine Dx Target Test using Ion Reporter Software.
  • Kaplan–Meier method and Cox proportional hazards model used to evaluate progression-free survival (PFS).
  • In patients with EGFR amplification, PFS for the ex19del subtype was longer (HR 0.41; p=0.061) while the L858R subtype showed shorter PFS (HR 1.72; p=0.266).
  • Overall PFS did not significantly differ by EGFR amplification status (median PFS: 18.4 vs. 15.6 months; p=0.63).
  • Significant EGFR amplification-by-subtype interaction was found (p=0.031), indicating that the benefit from osimertinib varies by EGFR mutation subtype.

Cite This Study

Murata et al. (2026) studied this question.

synapsesocial.com/papers/6a1a82640307b78509434139https://doi.org/10.1200/jco.2026.44.16_suppl.e20534
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical significance of <i>EGFR</i> amplification in patients with <i>EGFR</i> -mutated metastatic non–small cell lung cancer receiving first-line osimertinib.2026
  2. 2Clinical significance of <i>EGFR</i> amplification in patients with <i>EGFR</i> -mutated metastatic non-small cell lung cancer receiving first-line osimertinib2026
  3. 3Prognostic impact and treatment options for EGFR-mutant non-small cell lung cancer with concurrent EGFR amplification2026
  4. 4Association of MET overexpression with patient outcomes in <i>EGFR</i> -mutant lung adenocarcinoma treated with first-line osimertinib.2026
  5. 520P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients post osimertinib first line treatment failure: An interim analysis of GPS study2024 · 2 citations